This audit provides advice on the rationale behind providing a therapeutic switch from monitored release venlafaxine to normal release.
This audit provides information on risk avoidance for patients with dementia treated with anticholinergic medication.
This prescribing review protocol is based on the recommendations for the management of migraine made in SIGN Guideline 107 and the NHS D&G Joint Formulary. It covers the use of opiates in migrane, triptan overuse and formulary compliance.
Buspirone is licensed for the short-term management of anxiety disorders and the relief of symptoms of anxiety with or without accompanying depression.